The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
January 21st 2025
Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
Recent Developments in the Management of Heart Failure With Preserved Ejection Fraction
1.0 Credit / Cardiology
View More
Therapies in Lowering LDL-Cholesterol Levels for the Primary and Secondary Prevention of Atherosclerotic Cardi...
0.75 Credit / Cardiology
View More
Updated Guidelines in the Management of Atrial Fibrillation and Application for Pharmacists
1.5 Credits / Cardiology
View More
The Expanding Role of Nonstatin Therapies in Reducing LDL-Cholesterol Levels to Prevent and Manage ASCVD: A Re...
1.5 Credits / Cardiology
View More
Elevating Cardiac Care: Insights From Pharmacists Across Practice Settings
1.0 Credit / Cardiology
View More
The Evolving Treatment Paradigm for the Management of Pulmonary Arterial Hypertension: Strategies to Optimize ...
1.5 Credits / Cardiology
View More
Optimizing Care for Chronic Worsening Heart Failure: The Key Role of Pharmacists in Integrating Therapies
1.5 Credits / Cardiology
View More
Lipoprotein(a) and Beyond: Emerging Paradigms in Atherosclerotic Cardiovascular Disease Prevention
1.5 Credits / Cardiology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Harnessing the Potential of SGLT2 Inhibitors in Cardiorenal Metabolic Health: Strategies for Long-term Care an...
1.0 Credit / Cardiology, Endocrinology, Diabetes, & Metabolism, Nephrology
View More
Mastering Hypertrophic Cardiomyopathy: Cutting-Edge Therapies for Better Outcomes
1.5 Credits / Cardiology
View More
Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy
1.0 Credit / Cardiology
View More
Exploring Advances in the Management of DOAC-Associated Bleeding With Reversal Agents: Role of the Health-Syst...
1.5 Credits / Cardiology, Patient Safety
View More
FDA Approves Evinacumab-dgnb for Young Children With Homozygous Familial Hypercholesterolemia
March 22nd 2023Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.
Read More
Study: Linking Flu Vaccination, Potential Cardiovascular Benefits Increases Vaccination Rates
March 9th 2023Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.
Read More
ACC 2023 Session Highlights Need for Pharmacists in Cardio-Oncology Care Teams
March 6th 2023Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.
Read More
Bempedoic Acid Reduces Major Adverse Cardiovascular Events in Patients Who Cannot Tolerate Statins
March 4th 2023Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein-cholesterol.
Read More